MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
14.90
-0.10 (-0.67%)
At close: Dec 5, 2025, 4:00 PM EST
15.00
+0.10 (0.67%)
After-hours: Dec 5, 2025, 7:59 PM EST
MLTX Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for MLTX stock have an average target of 36.33, with a low estimate of 5.00 and a high estimate of 85. The average target predicts an increase of 143.83% from the current stock price of 14.90.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MLTX stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 3 | 4 |
| Buy | 5 | 5 | 4 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 8 | 8 | 7 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $26 | Strong Buy | Maintains | $30 → $26 | +74.50% | Nov 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $30 | Hold → Strong Buy | Upgrades | $30 | +101.34% | Nov 3, 2025 |
| Citigroup | Citigroup | Hold → Strong Sell Downgrades $5 | Hold → Strong Sell | Downgrades | $5 | -66.44% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $80 → $20 | Strong Buy | Maintains | $80 → $20 | +34.23% | Sep 30, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.63
from -1.89
EPS Next Year
-3.63
from -3.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.49 | -2.66 | ||||
| Avg | -3.63 | -3.63 | ||||
| Low | -3.62 | -4.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.